Dr. Hafrun Fridriksdottir was appointed Executive Vice President and Head of Teva’s Global Research and Development organization in November 2017. She oversees a global organization of ~3,500 colleagues responsible for the discovery, development, registration, medical affairs and patient safety activities for Teva’s generics, novel biologics and biosimilar pipeline and portfolio.

Prior to her current position, Dr. Fridriksdottir held R&D top management roles at Teva and other leading global pharmaceutical companies. Before being appointed Head of Global R&D at Teva, Dr. Fridriksdottir was President of Global Generics R&D at Teva. She held the positions of Senior Vice President and President of Global Generics R&D at Allergan plc from 2016, and from 2002 to 2015, she held leadership roles of increasing responsibility within the Actavis Group, including Senior Vice President of Global R&D. Dr. Fridriksdottir launched her business career at Omega Pharma, serving as Divisional Manager of Development until Omega’s merger with Actavis.

Dr. Frikdriksdottir received a Master of Science degree in Pharmacy and a PhD in Physical Pharmacy from the University of Iceland.